A Comprehensive Evaluation of the NAVITOR Transcatheter Aortic Valve Replacement System.

IF 1.9 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS
Heart International Pub Date : 2024-04-09 eCollection Date: 2024-01-01 DOI:10.17925/HI.2024.18.1.4
Joe Aoun, Syed Zaid, Sachin Goel, Michael J Reardon
{"title":"A Comprehensive Evaluation of the NAVITOR Transcatheter Aortic Valve Replacement System.","authors":"Joe Aoun, Syed Zaid, Sachin Goel, Michael J Reardon","doi":"10.17925/HI.2024.18.1.4","DOIUrl":null,"url":null,"abstract":"<p><p>Transcatheter aortic valve replacement (TAVR) has undergone significant advancements in the last two decades, expanding its indications and refining transcatheter heart valve (THV) and delivery system designs to improve procedural success and patient outcomes. This review focuses on the Navitor™ valve, a third-generation intra-annular Portico™ valve (Abbott Structural Heart, St Paul, MN, USA) designed to address TAVR complications, particularly paravalvular leak (PVL). We present an overview of the Navitor™ system, comparing it to the first-generation Portico™ THV in terms of THV design, key iterations and clinical outcomes. The Navitor™ THV introduces two key refinements-a protective outer sealing skirt and a more flexible delivery system. These enhancements have led to a significant reduction in 30 day PVL rates, from 6.3% with the first-generation Portico™ to 0% with the Navitor™ system. Additionally, the Navitor™ system exhibited lower rates of severe bleeding (27.3% versus 13.1%) and major vascular complications (5.8% versus 0.7%) compared with the first-generation Portico™. The Navitor™ valve represents a promising advancement in TAVR technology, with notable reductions in complications such as PVL, severe bleeding, and major vascular issues, compared with its predecessor. While further research is needed to assess long-term durability, these results underscore its potential benefits in enhancing patient outcomes and reducing complications. This review provides insights into the evolving landscape of TAVR technology and its quantifiable impact on patient care.</p>","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"18 1","pages":"26-29"},"PeriodicalIF":1.9000,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11239129/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Heart International","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17925/HI.2024.18.1.4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Transcatheter aortic valve replacement (TAVR) has undergone significant advancements in the last two decades, expanding its indications and refining transcatheter heart valve (THV) and delivery system designs to improve procedural success and patient outcomes. This review focuses on the Navitor™ valve, a third-generation intra-annular Portico™ valve (Abbott Structural Heart, St Paul, MN, USA) designed to address TAVR complications, particularly paravalvular leak (PVL). We present an overview of the Navitor™ system, comparing it to the first-generation Portico™ THV in terms of THV design, key iterations and clinical outcomes. The Navitor™ THV introduces two key refinements-a protective outer sealing skirt and a more flexible delivery system. These enhancements have led to a significant reduction in 30 day PVL rates, from 6.3% with the first-generation Portico™ to 0% with the Navitor™ system. Additionally, the Navitor™ system exhibited lower rates of severe bleeding (27.3% versus 13.1%) and major vascular complications (5.8% versus 0.7%) compared with the first-generation Portico™. The Navitor™ valve represents a promising advancement in TAVR technology, with notable reductions in complications such as PVL, severe bleeding, and major vascular issues, compared with its predecessor. While further research is needed to assess long-term durability, these results underscore its potential benefits in enhancing patient outcomes and reducing complications. This review provides insights into the evolving landscape of TAVR technology and its quantifiable impact on patient care.

对 NAVITOR 经导管主动脉瓣置换系统的全面评估。
过去二十年来,经导管主动脉瓣置换术(TAVR)取得了重大进展,扩大了适应症,改进了经导管心脏瓣膜(THV)和输送系统设计,提高了手术成功率和患者预后。本综述重点介绍 Navitor™ 瓣膜,它是第三代环内 Portico™ 瓣膜(雅培结构性心脏,美国明尼苏达州圣保罗市),旨在解决 TAVR 并发症,尤其是瓣膜旁漏 (PVL)。我们对 Navitor™ 系统进行了概述,并从 THV 设计、关键迭代和临床结果方面将其与第一代 Portico™ THV 进行了比较。Navitor™ THV 引入了两项关键改进--保护性外密封裙和更灵活的输送系统。这些改进显著降低了 30 天 PVL 率,从第一代 Portico™ 的 6.3% 降至 Navitor™ 系统的 0%。此外,与第一代 Portico™ 相比,Navitor™ 系统的严重出血率(27.3% 对 13.1%)和主要血管并发症发生率(5.8% 对 0.7%)更低。与前代产品相比,Navitor™瓣膜显著减少了PVL、严重出血和大血管问题等并发症,是TAVR技术的一大进步。虽然还需要进一步的研究来评估其长期耐久性,但这些结果凸显了其在提高患者预后和减少并发症方面的潜在优势。本综述深入探讨了 TAVR 技术不断发展的前景及其对患者护理的量化影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Heart International
Heart International Medicine-Cardiology and Cardiovascular Medicine
CiteScore
0.90
自引率
0.00%
发文量
9
审稿时长
7 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信